Tech Company Financing Transactions
Poplar Therapeutics Funding Round
Poplar Therapeutics, based in Denver, secured $45 million from Janus Henderson Investors, RA Capital and SR One Capital Management.
Transaction Overview
Company Name
Announced On
3/4/2026
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to support further clinical development of lead program PHB-050 in food allergy and other atopic conditions
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
100 Fillmore Street 500
Denver, CO 80206
USA
Denver, CO 80206
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
We are on a mission to create the next generation of anti-IgE medicines so patients can live free of fear.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Chip Baird
Browse more venture capital transactions:
Prev: 3/4/2026: Breezeway venture capital transaction
Next: 3/4/2026: Mutable Tactics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions on this site are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs